IL137247A0 - Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications - Google Patents

Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications

Info

Publication number
IL137247A0
IL137247A0 IL13724799A IL13724799A IL137247A0 IL 137247 A0 IL137247 A0 IL 137247A0 IL 13724799 A IL13724799 A IL 13724799A IL 13724799 A IL13724799 A IL 13724799A IL 137247 A0 IL137247 A0 IL 137247A0
Authority
IL
Israel
Prior art keywords
reducing conditions
applications
sensitive
transfecting
pharmaceutical compositions
Prior art date
Application number
IL13724799A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9801065A external-priority patent/FR2774394B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL137247A0 publication Critical patent/IL137247A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13724799A 1998-01-30 1999-01-28 Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications IL137247A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9801065A FR2774394B1 (fr) 1998-01-30 1998-01-30 Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
US7702698P 1998-03-06 1998-03-06
PCT/FR1999/000162 WO1999038821A2 (fr) 1998-01-30 1999-01-28 Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications

Publications (1)

Publication Number Publication Date
IL137247A0 true IL137247A0 (en) 2001-07-24

Family

ID=26234096

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13724799A IL137247A0 (en) 1998-01-30 1999-01-28 Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications

Country Status (14)

Country Link
US (1) US6521252B1 (zh)
EP (1) EP1049793B1 (zh)
JP (1) JP2002501762A (zh)
KR (1) KR20010081924A (zh)
CN (1) CN1289371A (zh)
AT (1) ATE306556T1 (zh)
AU (1) AU759197B2 (zh)
BR (1) BR9907269A (zh)
CA (1) CA2318512C (zh)
DE (1) DE69927669T2 (zh)
HU (1) HUP0101393A3 (zh)
IL (1) IL137247A0 (zh)
NO (1) NO20003880D0 (zh)
WO (1) WO1999038821A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
WO2002028367A1 (fr) * 2000-10-04 2002-04-11 Kyowa Hakko Kogyo Co., Ltd. Procede de revetement de particules fines avec un film de lipides
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
FR2921369B1 (fr) * 2007-09-25 2014-07-11 Pf Medicament Nouveau procede de preparation de derives (poly) aminoalkylaminoacetamide d'epipodophyllotoxine,utiles pour leurs applications en therapeutique comme agent anticancereux.
GB0720486D0 (en) * 2007-10-19 2007-11-28 Univ Edinburgh Cationic lipids
JP6762094B2 (ja) * 2013-02-28 2020-09-30 タフツ ユニバーシティー 薬剤のデリバリーのためのジスルフィド化合物
US11433128B2 (en) * 2017-04-07 2022-09-06 Tianxin Wang Cell surface anchoring antigen conjugates to treat cancer
WO2019160780A1 (en) * 2018-02-16 2019-08-22 Wang tian xin Methods and agents to treat tumor cells and cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
EP0537299A1 (en) 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
WO1996040627A2 (en) 1995-06-07 1996-12-19 Gen-Probe Incorporated Thiocationic lipids, pharmaceutical compositions and methods of use thereof
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP0945138A1 (en) 1997-12-04 1999-09-29 Université Louis Pasteur de Strasbourg Transfection particles
US6169078B1 (en) 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances

Also Published As

Publication number Publication date
KR20010081924A (ko) 2001-08-29
CA2318512A1 (fr) 1999-08-05
HUP0101393A1 (hu) 2001-08-28
AU4384300A (en) 2001-04-05
WO1999038821A3 (fr) 1999-09-23
NO20003880L (no) 2000-07-28
CN1289371A (zh) 2001-03-28
HUP0101393A3 (en) 2004-10-28
ATE306556T1 (de) 2005-10-15
WO1999038821A2 (fr) 1999-08-05
AU759197B2 (en) 2003-04-10
EP1049793A2 (fr) 2000-11-08
DE69927669D1 (de) 2006-02-23
JP2002501762A (ja) 2002-01-22
EP1049793B1 (fr) 2005-10-12
US6521252B1 (en) 2003-02-18
NO20003880D0 (no) 2000-07-28
DE69927669T2 (de) 2006-07-20
CA2318512C (fr) 2009-10-13
BR9907269A (pt) 2001-04-03

Similar Documents

Publication Publication Date Title
ZA961255B (en) Pharmaceutical composition containing nucleic acids and uses thereof
AU1458395A (en) Composition containing nucleic acids, preparation and uses
PL336983A1 (en) Compounds, their production and application as carriers of nucleic acids in cells
NZ512792A (en) Stable liquid interferon beta formulations
ATE328069T1 (de) Phosphopantethenyltransferasen und deren verwendungen
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
IL115199A0 (en) Nucleic acid delivery vehicle
EP1775345A3 (en) Vector constructors
IL137247A0 (en) Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications
WO2000009677A3 (en) Sterol-regulated site-1 protease and assays of modulators thereof
NZ334518A (en) Homocysteine desulphurase from the protozoan trichomonas vaginalis
MX9806041A (es) Proteina purificada sr-p70.
HUP0102413A1 (hu) Vektorok nukleinsavak bevitelére, ezeket tartalmazó készítmények és alkalmazásuk
AU4513099A (en) Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
DE69535024D1 (de) Verpackungszellinie zur transkomplementierung von defektiven retroviren-vektoren
HUP0200345A2 (hu) Új nukleinsav-transzferáló ágensek, ezeket tartalmazó készítmények és alkalmazásuk
HUP0102455A2 (hu) Új nukleinsav-transzfer ágensek, ezeket tartalmazó készítmények és alkalmazásuk
MD1328G2 (ro) Mediu nutritiv pentru cultivarea drojdiei Sporobolomyces peraroseus
WO1999059638A8 (en) Compositions and methods for the delivery of nucleic acid molecules
WO2000034500A3 (en) Methods for increasing the efficiency of gene transfer
AU7771100A (en) Development of an effective gene transfer technique for introducing foreign dna into sperm cells
ZA99694B (en) Transfecting compounds which are sensitive to reducing conditions, pharmaceutical compositions containing them and their applications.
AU3992499A (en) Compositions and methods for the delivery of nucleic acid molecules